Abbot receives CE Mark for Tecnis Symfony extended range of vision IOL

Article

Abbott recently announced it has received CE Marking (Conformité Européenne) in Europe for the Tecnis Symfony extended range of vision intraocular lens (IOL) for the treatment of cataract patients who may also have presbyopia.

Abbott Park, IL-Abbott recently announced it has received CE Marking (Conformité Européenne) in Europe for the Tecnis Symfony extended range of vision intraocular lens (IOL) for the treatment of cataract patients who may also have presbyopia.

According to Abbott, the Tecnics Symfony IOL is intended to provide a continuous range of vision, including far, intermediate, and near distances with reduced incidence of halo and glare comparable to a monofocal lens. The Tecnis Symfony IOL is not approved for use in the United States. 

Abbott began a 150-patient study in Europe to evaluate patients' quality of vision at far, intermediate, and near distances after being implanted in both eyes with the Tecnis Symfony IOL. The study will also assess both patient and surgeon satisfaction. Preliminary study results are anticipated later this year. The company is also conducting a post-market observational study with approximately 400 patients across Europe, including the United Kingdom, France, Germany, and Spain, with results expected at the end of 2014.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO
Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO
EyeCon Co-chair Oluwatosin U. Smith, MD talks passion for research and education in ophthalmology
Eyerie Academics cofounders discuss the organization's future and preparing optometric students
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Sherrol A. Reynolds, OD, speaks about highlights from the 2024 NOA Convention
A. Philip Aitsebaomo, O.D., Ph.D. outlines his talk on treating patients with prosthetic eyes
© 2024 MJH Life Sciences

All rights reserved.